To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
A team from the I2BC publishes in FEBS Journal an exhaustive review of the various mutations affecting the structure of type A lamins, proteins that make up the envelope of the cell nucleus (nuclear lamina), which lead to premature aging in people with the disease (Progeria).
A team from SPI in Marcoule detected by mass spectrometry, in 3 minutes and without specific reagents, signature peptides of the SARS-CoV-2 virus in clinical samples (nasopharyngeal swabs). It thus provides a proof of concept of the use of this method as a possible alternative to PCR, currently the reference method.
The SENIOR study, conducted by several NeuroSpin teams, consists in monitoring, since March 2012, a cohort of 100 subjects aged 50 to 70 years by annual MRI imaging over a period of 10 years, to establish a normal aging brain imaging biomarkers mapping. This publication in Alzheimer's Research & Therapy describes the baseline experimental protocol and presents first promising results.
A NeuroSpin team, in collaboration with researchers from SHFJ and MIRCen (CEA-Jacob), is identifying a predictive indicator of the potentially deleterious effect of devices using ultrasound to deliver drugs to the brain.
Researchers at the Institut de Recherche Saint Louis and I2BC identify a protein motif responsible for the specificity of insertion of retrotransposon Ty1 in the yeast genome. This motif could be used to adapt gene therapy vectors and limit their mutagenic potential.
The international OpenGATE collaboration, involving the BioMaps laboratory[1](SHFJ), has demonstrated the value of the GATE numerical simulation platform in clinical use for cancer treatment planning using hadrontherapy.
In an article published in the Journal of Medicinal Chemistry, the Venomics consortium led by a SIMoS team shows the interest of creating toxin banks to identify molecules regulating therapeutic targets.
The discovery of myriads of new species of bacteria and archaea, linked to the explosion of metagenomics, is leading microbiologists to consider rethinking how to map certain branches of life. Tools, such as the phylopeptidomics developed at Li2D, could help them do so.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.